ResMed Inc. vs VICI Properties Inc — how do they compare? ResMed Inc. trades at $225.92 (market cap $31.78B), while VICI Properties Inc trades at $22.9 (market cap $24.93B). The key difference: ResMed Inc. is the larger of the two by market cap, and VICI Properties Inc pays the higher dividend (8.13%). Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and VICI Properties Inc for 42 Days on average.
| RMD | VICI | |
|---|---|---|
Market Cap | $31.78B | $24.93B |
Volume | 1,128,382 | 9,679,693 |
Sector | Health | Real Estate |
52-Week High | $277.88 | $31.42 |
52-Week Low | $182.82 | $22.53 |
Typical Hold Time | 51 Days | 42 Days |
Enterprise Value | $31.14B | $42.48B |
Dividend Yield | 1.17% | 8.13% |
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical outlook supported by moving averages and strong fundamentals. The company reported revenue of $5.15B in 2025, with net income of $1.40B and robust margins. Recent earnings beats and a dividend announcement highlight operational strength, while analyst consensus leans positive with a $242.70 price target.
Outlook remains favorable due to consistent EPS growth and market share gains, though risks include competitive pressures and ongoing legal investigations. The stock offers growth potential from healthcare demand tailwinds, but investors should monitor execution against guidance and macroeconomic factors affecting medical device spending.
VICI Properties trades at $22.64, down 0.4% on the day, with a bearish technical signal driven by moving averages. The stock shows attractive valuation metrics, including a P/E of 8.78 and P/B of 0.85, alongside strong profitability with a net income margin of 67.5%. Recent earnings have been mixed, with a beat in Q1 2026 but misses in Q4 2025 and Q2 2026. The company maintains robust cash flow from operations of $2.51 billion in 2025 and recently announced a dividend of $0.46 per share payable in October 2026.
The outlook for VICI is supported by solid fundamentals and a 75% analyst buy rating, with a consensus price target of $28.90 implying significant upside. However, risks include tenant concentration concerns, as highlighted in recent news, and the bearish technical trend. The stock offers value and income potential but faces headwinds from market sentiment and interest rate sensitivity.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →